Le Lézard
Classified in: Health, Science and technology
Subjects: CSR, ESG

BGI Group Included in First Fortune China ESG List


SHENZHEN, China, Aug. 24, 2022 /PRNewswire/ -- BGI Group is featured among the top companies in China in Fortune China's inaugural China ESG list, published this week.

As Fortune China notes in their introduction to the list of 40 featured companies, they were delighted to find that although ESG is a foreign concept, there have been many active practitioners across various industries in China.

Fortune China highlighted four achievements by BGI Group for inclusion on the list:

"While we are honored to receive this recognition of our ESG work, BGI Group has always been focused on the development of life sciences for the betterment of mankind," said a BGI Group spokesperson. "Everything we do should be focused on improving lives, which is why our work includes ground-breaking science discoveries, innovative research into microbiology and biodiversity, diagnostic testing services to trace viruses and diseases, and the development of next generation technologies for large-scale gene sequencing."


These press releases may also interest you

at 21:59
Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology...

at 21:27
Labcorp , a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed,...

at 21:19
Invitae , a leading medical genetics company, announced that Labcorp , a global leader of innovative and comprehensive laboratory services, has been selected...

at 21:05
Valcare Medical, Inc., a leading innovator in transcatheter-based mitral...

at 21:02
Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that results from four clinical studies of the company's three key...

at 19:59
Genomma Lab Internacional, S.A.B. de C.V. (BMV: LAB B) ("Genomma" or "the Company"), today announced its results for the first quarter of 2024. All figures included herein are stated in nominal Mexican pesos and have been prepared in accordance with...



News published on and distributed by: